Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST PHARMACEUTICALS INC

Form 4

December 31, 2015

1. Title of 2.

3. Transaction Date 3A. Deemed

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

FORM	ЛД								PPROVAL		
1 01111	UNITED	STATES S					COMMISSION	CIVID	3235-028		
Check t	his box		Wa	shington	, D.C. 20)549		Number:			
if no lor	nger		CILAN	ICEC IN	DENIER			Expires:	January 31 200		
subject Section Form 4	to STATEN 16.	MENI OF	F CHANGES IN BENEFICIAL OWNERSHIP O SECURITIES					Estimated average burden hours per response 0.			
Form 5 obligation may con See Inst	ons ntinue. Section 17(Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type	Responses)										
1. Name and Address of Reporting Person ** Powell Lynne			2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS				5. Relationship of Reporting Person(s) to Issuer				
		INC [BCRX]				(Check all applicable)					
(Last) (First) (Middle) 4505 EMPEROR BLVD., SUITE			3. Date of Earliest Transaction (Month/Day/Year) 12/29/2015				below)	X_ Officer (give title Other (specify			
200											
		4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting					
DURHAM	I, NC 27703						Person	Aore than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	acquired, Disposed o	f, or Beneficia	ally Owned		
(Instr. 3) any		Execution D	Date, if Transact Code		4. Securit nAcquired Disposed (Instr. 3,	(A) or of (D)	Securities Beneficially (Owned (Following (Reported Transaction(s)	6. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Price	(Instr. 3 and 4)				
Reminder: Re	eport on a separate line	e for each class	s of secu	urities bene	-	-	•				
					inforn requii	nation cont red to respo ays a curre	spond to the collectained in this form ond unless the form only valid OMB cor	are not m	SEC 1474 (9-02)		
	Tab			-		posed of, or convertible	Beneficially Owned securities)				

7. Title and Amount of

Underlying Securities

5. Number of 6. Date Exercisable and

Expiration Date

OMB APPROVAL

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)		
				Code '	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Emp. Stock Option (Right to Buy)	\$ 10.82	12/29/2015		A	(62,573 (1)		12/29/2016	12/29/2025	Common Stock	62,573

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Powell Lynne

4505 EMPEROR BLVD.

SUITE 200 Senior VP - CCO

DURHAM, NC 27703

Signatures

/s/ Alane P. Barnes, by power of attorney 12/31/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2